AU · rank #13 · 2026-09-04
SENS
NASDAQ · $496M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.452 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.24 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 5 |
| Insider signal (90d) $125,300 across 1 unique buyers. | 2.409 |
| Analyst upside Consensus target $13.40 | +35.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +36.32% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.50 |
| Gross margin TTM | +54.9% |
| 52w high | $11.58 |
| Market cap (USD) | $496M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Senseonics Holdings, Inc. designs and commercializes long-term, implantable continuous glucose monitoring (CGM) systems, notably the Eversense E3 and newly launched Eversense 365, for diabetes management [1, 2].
Rationale
Strong analyst upward revision agreement of 85.7% and 35.4% upside are fundamentally validated by a 120% year-over-year Q2 2026 revenue increase and raised full-year guidance following the FDA clearance of Eversense 365 [1].
Material risks
- 1Intense competition from dominant, entrenched manufacturers of non-implantable transcutaneous CGMs (such as Dexcom and Abbott) could restrict mainstream adoption of Senseonics' implantable sensors [1, 2].
- 2High capital expenditure and persistent operating losses—highlighted by a $36.7 million net loss in Q2 2026—create severe ongoing dilution risks due to the company's reliance on external capital [1].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.